Status:
WITHDRAWN
Evaluating the Efficacy of Artesunate in Adults With Mild Symptoms of COVID-19
Lead Sponsor:
Princess Nourah Bint Abdulrahman University
Conditions:
Covid 19 Positive
Corona Virus Infection
Eligibility:
All Genders
18-60 years
Phase:
PHASE2
Brief Summary
Coronavirus disease (COVID-19) is an infectious disease caused by a newly discovered coronavirus. At this time, there are no specific vaccines or treatments for COVID-19. However, there are many ongo...
Detailed Description
In this Clinical trial, Investigators will evaluate the effect of Artemisinin / Artesunate on morbidity of COVID-19 patients in decreasing the course of the disease and viral load in symptomatic stabl...
Eligibility Criteria
Inclusion
- Adult patient age more than 18 and less than 60 years
- Symptomatic , positive swab covid-19 patients
- Patients who have mild to moderate symptoms
- Patients who have no risk factors like
- Patients who is not on other medications rather those on supportive care
Exclusion
- · Patients who have sever disease- shortness of breath, sick patients or admitted in ICU
- Patients who are receiving ventilation supports
- High risk group like :- age more than 60 years, chronic heart diseases, chronic lungs diseases, diabetes, immunocompromised diseases or on immune suppression medications or pregnant women
- Patients who are on other medications which used as treatment for covid 19
Key Trial Info
Start Date :
January 1 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2022
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT04387240
Start Date
January 1 2022
End Date
December 1 2022
Last Update
May 2 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Princess Nourah Bint Abdulrahman Univeristy
Riyadh, Central, Saudi Arabia, 11552